Ovarian cancer remains one of the most lethal gynecologic cancers in the United States. High-grade serous ovarian carcinoma (HGSC), the most common subtype, is often diagnosed at an advanced stage when treatment options are limited. Standard therapies typically include surgery and chemotherapy, but recurrence rates remain high. In recent years, researchers have turned to immunotherapy—a treatment that boosts the body’s natural defenses—to improve outcomes. Unfortunately, immunotherapy has shown only modest success against ovarian cancer. A new study helps explain why.
The role of Trp53 in ovarian cancer
Published in the journal Oncotarget (September 22, 2025), the study examined the impact of losing the Trp53 gene, one of the most important tumor suppressors. The research team, led by Jacob Haagsma and Dr. Trevor G. Shepherd from Western University in Canada, discovered that removing this gene not only made tumors grow more aggressively but also weakened the immune system’s ability to respond.
How the study was conducted
To closely mimic the progression of human HGSC, scientists developed a specialized mouse model. They introduced ovarian epithelial cells—with and without Trp53—into the fallopian tubes, the origin site of most ovarian cancers. This allowed the researchers to observe how tumors developed in a realistic biological setting.
Key findings on tumor growth and immune activity
The results were striking. Mice injected with cells lacking Trp53 developed tumors that were faster-growing, more invasive, and more resistant to immune attack. In these tumors, T cells—the white blood cells that typically help destroy cancer—were present in lower numbers and functioned less effectively. The few T cells that remained showed signs of being “exhausted,” meaning they were less capable of fighting the disease.
Reduced inflammatory signaling
Further analysis showed that tumor cells without Trp53 had weaker activation of inflammation-related genes. These genes normally produce proteins that signal the immune system to attack cancer. When the tumors spread into the abdominal cavity, a condition that resembles advanced ovarian cancer in patients, immune signaling became even weaker. This created an environment where cancer cells could thrive without much interference from the immune system.
Implications for ovarian cancer treatment
The study highlights how genetic mutations like Trp53 loss can dramatically change the relationship between cancer and the immune system. By reducing immune surveillance, tumors gain a significant advantage in growing and spreading. This may explain why many ovarian cancer patients do not respond well to immunotherapy alone.
According to the researchers, understanding these mechanisms could lead to new treatment strategies. For example, therapies designed to restore or compensate for Trp53 function, or to boost inflammatory signaling, might improve the effectiveness of immunotherapy. In addition, these findings could help identify which patients are most likely to benefit from specific treatment approaches.
Looking ahead
Ovarian cancer research is moving toward more personalized medicine. This study underscores the importance of considering both the genetic profile of tumors and the tumor’s immune environment when developing therapies. As Dr. Shepherd’s team notes, targeting the pathways influenced by Trp53 loss could open new doors in the fight against this devastating disease.
Related topics
Precision Radiosurgery Offers Hope for Ovarian Cancer Brain Spread
Breast And Ovarian Cancer Cases In Women Expected To Rise By 2050
Breastfeeding Safe After Breast Cancer, May Support Postpartum Mental Health
